Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

@article{Long2014CombinedBA,
  title={Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.},
  author={Georgina V. Long and Daniil Stroyakovskiy and Helen J. Gogas and Evgeny V. Levchenko and Filippo Guglielmo de Braud and J. Bradley Larkin and Claus Garbe and Thomas Jouary and Michal Starnawski and Jean-Jacques Grob and Vanna Chiarion Sileni and Celeste Lebb{\'e} and Maurizio Mandal{\`a} and Michael J. Millward and Ana M Arance and Igor E Bondarenko and John B A G Haanen and Johan Hansson and Jochen Sven Utikal and Virginia Ferraresi and Nadezhda Kovalenko and Peter Mohr and Volodymyr Probachai and Dirk Schadendorf and Paul N. Nathan and C. Brooks Robert and Antoni Ribas and Douglas J Demarini and Jhangir G. Irani and Michelle Stanley Casey and Daniele Ouellet and A. Mart{\'i}n and Ngocdiep T. Le and Kiran Mahendrabhai Patel and Keith T Flaherty},
  journal={The New England journal of medicine},
  year={2014},
  volume={371 20},
  pages={
          1877-88
        }
}
BACKGROUND Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations. METHODS In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or… CONTINUE READING

Similar Papers

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 491 CITATIONS, ESTIMATED 47% COVERAGE

Trametinib in the treatment of melanoma.

  • Expert opinion on biological therapy
  • 2015
VIEW 19 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

[Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges].

  • Deutsche medizinische Wochenschrift
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

[Innovative therapies for metastatic melanoma in elderly patients].

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 22 Highly Influenced Citations

  • Averaged 79 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

  • The New England journal of medicine
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

quired resistance and clonal evolution in melanoma during BRAF inhibitor thera

G Hatzivassiliou, K Song, I Yen
  • Cancer Discov
  • 2014